RNAZ transcodetherapeutics.com: Market Capitalization to Book Value Ratio

RNAZ (TransCode Therapeutics Inc.) - company brandmark

TransCode Therapeutics (RNAZ) develops RNA-based cancer drugs protected by patents against dumping. This market-to-book value chart visualizes asset valuation dynamics, where -0.06 reflects the metric's baseline. Current momentum is driven by investments, as operational cash flow has not yet commenced. Development remains independent of economic cycles, depending solely on capital availability.

transcodetherapeutics.com (RNAZ): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for TransCode Therapeutics (RNAZ)

- price and consensus price forecast:
Stock Quotes transcodetherapeutics.com|RNAZ - Forecast Levels Chart
- market capitalization data:
Market Capitalization TransCode|RNAZ - Business Value
- book capitalization data:
Net Assets per Single Share TransCode Therapeutics|RNAZ - Accounting Capitalization|Market Capitalization to Book Value Ratio transcodetherapeutics.com|RNAZ - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio TransCode Therapeutics|RNAZ - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity transcodetherapeutics.com|RNAZ - Aggregate Debt Obligations|Debts to Book Capitalization TransCode
Initial company analysis:TransCode Therapeutics Inc. - RNAZ
Mass-produced product of transcodetherapeutics.com

This indicator measures the premium of a business's market value over its net assets. For the biopharmaceutical innovator TransCode Therapeutics (RNAZ), this gap reflects the capitalization of the TTX platform's intellectual potential. By analyzing the ratio of the company's market capitalization to its book value, one can assess investor expectations for R&D projects. An increasing multiple confirms the market's confidence in its technological leadership in oncology, while extreme values signal that the asset is overbought.

Direct competitors

Market Cap to Net Assets Ratio Tempus Labs (TEM)|qiagen.com (QGEN) - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio Ionis (IONS)|Capitalization to Book Value Ratio RGEN|Market Value to Book Value Ratio Avidity RNA|Capitalization to Book Value Ratio CRISPR (CRSP)|Market Capitalization to Book Value Ratio WGS (GeneDx Holdings Corp.)|RARE - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Beam Therapeutics BEAM|SRPT: Market Cap to Book Value Multiple|Market Value to Book Value Ratio Twist Bio TWST|10x (TXG) - Market Value to Book Value|NTLA (Intellia Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio STOK|Market Value to Book Value Ratio BioLife Solutions BLFS|Capitalization to Book Value Ratio WVE (Wave Life Sciences Ltd)|Market Value to Book Value Ratio MAZE|Market Capitalization to Book Value Sionna Corp SION|PRME: Market Capitalization to Book Value Ratio|TSHA: Market Cap to Net Assets Ratio|Market Value to Book Value Ratio QURE|MeiraGTx Holdings (MGTX) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Regenxbio (RGNX)|Capitalization to Book Value Ratio Solid Corp|Ocugen, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio pacb.com PACB|Market Cap to Net Assets Ratio Benitec Biopharma|DSGN - Market Value to Book Value|Market Cap to Net Assets Ratio Rocket Pharmaceuticals Inc RCKT|FDMT - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio lexeotx.com LXEO|Korro Bio (KRRO) - Market Value to Book Value|Market Capitalization to Book Value Ratio EDIT (Editas Medicine)|Market-to-Book Ratio SLN|ProQR Therapeutics N.V. (PRQR) - Market Value to Book Value Ratio|Market Value to Book Value codexis.com (CDXS)|Market Capitalization to Book Value Ratio SGMO (Sangamo Therapeutics)|Nautilus Biotechnology, Inc. - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Metagenomi|DTIL - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio GBIO|Market-to-Book Ratio Boundless Bio Inc|XCUR (Exicure Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Celsion Corporation (IMNN)|Market Cap to Net Assets Ratio Phio Pharmaceuticals|Market Cap to Book Value Multiple mustangbio.com (MBIO)|Market Capitalization to Book Value Ratio BNGO|Market Capitalization to Book Value Applied DNA Corp APDN|BLUE: Market Capitalization to Book Value Ratio|IPA: Market Cap to Net Assets Ratio|Omega Therapeutics, Inc. - Market Value to Book Value Ratio|OMIC (Singular Genomics Systems, Inc.) - Market Capitalization to Book Value|RGLS - Market Value to Book Value Ratio|Market Value to Book Value SYRS|Market Value to Book Value Ratio Telesis Bio, Inc. TBIO|Capitalization to Book Value Ratio traconpharma.com (TCON)|Market Capitalization to Book Value Ratio UBX (Unity Biotechnology, Inc.)